Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zaltrap,ZALTRAP2023US001,2023,USA,MDV,350,68,42,58,27.5,35,85,12,10,25,40,25,30,35,20,15,15,30,35,18,8,5,10,7,22,45,30,FOLFOX,CAPOX,CAPOX,FOLFOX,0,0,0,40,65,55,15,45,40,60,2
Zaltrap,ZALTRAP2022EU002,2022,Germany,Claim Database,420,72,38,62,26.8,40,78,15,8,22,45,25,28,32,25,15,12,28,40,20,10,6,12,8,25,40,35,FOLFOX,FOLFIRI,CAPOX,FOLFOX,0,0,0,45,70,60,20,50,30,55,3
Zaltrap,ZALTRAP2024JP003,2024,Japan,MDV,280,65,45,55,24.5,25,90,10,12,28,35,25,35,30,20,15,18,32,30,15,6,4,8,6,20,50,25,FOLFOX,XELOX,XELOX,FOLFOX,0,0,0,35,60,50,10,40,50,70,1.5
